Full Press Release Details
InflaRx Continues U.S. Expansion with
Addition of New York City Corporate Office and Addition of Management
Germany and NEW YORK, Jan. 03, 2019 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing
innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of
the innate immune system, today announced the opening of the company's second U.S. based location and the addition of new
management members. The new corporate office follows the opening of the company's R&D facility in Ann Arbor, MI in June
2018. The new facility will be part of InflaRx Pharmaceuticals Inc., a wholly owned subsidiary of the InflaRx N.V. group.
(formerly of Bausch Health) newly joins the InflaRx C-suite as Chief Legal Officer/General Counsel. Recently, Jordan Silverstein
(formerly of Advanced Accelerator Applications) joined InflaRx as Head of Corporate Strategy/Development. Both will be based in
the New York City office.
to grow our U.S. footprint marks a significant step in the evolution of InflaRx," said Prof. Niels Riedemann, MD, Chief
Executive Officer of InflaRx. "With our phase IIb data for IFX-1 in hidradenitis suppurativa on track for the first half
of this year, the ANCA-associated vasculitis trial continuing enrollment, and our focus on pipeline expansion - it is now
critical for us to add a strong corporate presence into the U.S. We are very pleased that we were able to attract a team with a
track record of industry success to anchor this new facility, while strategically placing us in an area critical to our progress
as a U.S. Nasdaq listed company."
a first-in-class monoclonal anti-complement factor C5a antibody which completely blocks biological activity in and demonstrates
high selectivity towards its target, C5a in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9)
intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated
to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key "amplifier"
of this response in pre-clinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development
and has, to date, successfully completed three clinical phase II studies. To date, more than 150 people have been treated with
IFX-1, which has been shown to be well tolerated. IFX-1 is currently
being developed for various inflammatory indications, including hidradenitis suppurativa and ANCA-associated vasculitis.
InflaRx (Nasdaq:IFRX)
is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop
first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression
of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich,
Germany and New York, NY, USA, as well as a research facility in Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select
Market in the United States under the trading symbol "IFRX".
Development and Strategy
Jordan.silverstein[at]inflarx.de
inflarx[at]mc-services.eu
release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as "may," "will," "should," "expect,"
"plan," "anticipate," "could," "intend," "target," "project,"
"estimate," "believe," "estimate," "predict," "potential" or "continue"
and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements
regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our
ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and
obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop
commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect
the industry or us and the risks uncertainties and other factors described under the heading "Risk Factors" in InflaRx'
periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release
and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements,
and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future,
except as required by law.